The global drugs for vancomyci-resistant enterococcus faecium market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing number of infections caused by vancomyci-resistant enterococcus faecium and the high mortality rate associated with these infections. The increasing prevalence of these infections in hospitals and clinics has led to an increase in demand for drugs that can treat them. The global drugs for vancomyci-resistant enterococcus faecium market is segmented on the basis of type, application, and region. On the basis of type, it is segmented into daptomycin, linezolid, quinupristin/dalfopristin, ampicillin, chloramphenicol; on the basis of application it is segmented into hospital and clinic; on the basis of region it is segmented into North America (US, Canada), Latin America (Mexico), Europe (Germany), Asia Pacific (China) and Middle East & Africa (Saudi Arabia).
Some Of The Growth Factors Of This Market:
- The increasing prevalence of antibiotic-resistant bacteria is a major factor driving the growth of the global drugs for vancomycin-resistant enterococcus faecium market.
- The increasing number of hospital acquired infections is also a major factor driving the growth of the global drugs for vancomycin-resistant enterococcus faecium market.
- The increasing number of patients with chronic diseases such as diabetes and cancer is also a major factor driving the growth of the global drugs for vancomycin-resistant enterococcus faecium market.
- Increasing awareness about drug resistant bacteria among healthcare professionals and patients is also a major factor driving the growth of the global drugs for vancomycin-resistant enterococcus faecium market.
- Increasing research and development activities in this field are expected to fuel demand over time.
Industry Growth Insights published a new data on “Drugs for Vancomycin-Resistant Enterococcus Faecium Market”. The research report is titled “Drugs for Vancomycin-Resistant Enterococcus Faecium Market research by Types (Daptomycin, Linezolid, Quinupristin/dalfopristin, Ampicillin, Chloramphenicol, Others), By Applications (Hospital, Clinic, Others), By Players/Companies Alchemia Limited, Alvogen, Aphios Corporation, Cellceutix Corporation, Enanta Pharmaceuticals, Helix BioMedix, LegoChem Biosciences, Lytix Biopharma, MGB Biopharma Limited, Microbiotix”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Drugs for Vancomycin-Resistant Enterococcus Faecium Market Research Report
By Type
Daptomycin, Linezolid, Quinupristin/dalfopristin, Ampicillin, Chloramphenicol, Others
By Application
Hospital, Clinic, Others
By Companies
Alchemia Limited, Alvogen, Aphios Corporation, Cellceutix Corporation, Enanta Pharmaceuticals, Helix BioMedix, LegoChem Biosciences, Lytix Biopharma, MGB Biopharma Limited, Microbiotix
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Report Segments:
The global Drugs for Vancomycin-Resistant Enterococcus Faecium market is segmented on the basis of:
Types
Daptomycin, Linezolid, Quinupristin/dalfopristin, Ampicillin, Chloramphenicol, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alchemia Limited
- Alvogen
- Aphios Corporation
- Cellceutix Corporation
- Enanta Pharmaceuticals
- Helix BioMedix
- LegoChem Biosciences
- Lytix Biopharma
- MGB Biopharma Limited
- Microbiotix
Highlights of The Drugs for Vancomycin-Resistant Enterococcus Faecium Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Daptomycin
- Linezolid
- Quinupristin/dalfopristin
- Ampicillin
- Chloramphenicol
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Drugs for Vancomycin-Resistant Enterococcus Faecium Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Vancomycin-resistant Enterococcus faecium is a type of bacteria that is resistant to the antibiotic vancomycin. Drugs used to treat this infection include other antibiotics, such as ampicillin or penicillin.
Some of the major players in the drugs for vancomycin-resistant enterococcus faecium market are Alchemia Limited, Alvogen, Aphios Corporation, Cellceutix Corporation, Enanta Pharmaceuticals, Helix BioMedix, LegoChem Biosciences, Lytix Biopharma, MGB Biopharma Limited, Microbiotix.
The drugs for vancomycin-resistant enterococcus faecium market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Drugs for Vancomycin-Resistant Enterococcus Faecium Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Drugs for Vancomycin-Resistant Enterococcus Faecium Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Drugs for Vancomycin-Resistant Enterococcus Faecium Market - Supply Chain
4.5. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Forecast
4.5.1. Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size (000 Units) and Y-o-Y Growth
4.5.3. Drugs for Vancomycin-Resistant Enterococcus Faecium Market Absolute $ Opportunity
5. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Type
5.3.1. Daptomycin
5.3.2. Linezolid
5.3.3. Quinupristin/dalfopristin
5.3.4. Ampicillin
5.3.5. Chloramphenicol
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Demand Share Forecast, 2019-2026
9. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Type
9.7.1. Daptomycin
9.7.2. Linezolid
9.7.3. Quinupristin/dalfopristin
9.7.4. Ampicillin
9.7.5. Chloramphenicol
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Demand Share Forecast, 2019-2026
10. Latin America Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Type
10.7.1. Daptomycin
10.7.2. Linezolid
10.7.3. Quinupristin/dalfopristin
10.7.4. Ampicillin
10.7.5. Chloramphenicol
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Drugs for Vancomycin-Resistant Enterococcus Faecium Demand Share Forecast, 2019-2026
11. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Type
11.7.1. Daptomycin
11.7.2. Linezolid
11.7.3. Quinupristin/dalfopristin
11.7.4. Ampicillin
11.7.5. Chloramphenicol
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Demand Share, 2019-2026
12. Asia Pacific Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Type
12.7.1. Daptomycin
12.7.2. Linezolid
12.7.3. Quinupristin/dalfopristin
12.7.4. Ampicillin
12.7.5. Chloramphenicol
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Drugs for Vancomycin-Resistant Enterococcus Faecium Demand Share, 2019-2026
13. Middle East & Africa Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size and Volume Forecast by Type
13.7.1. Daptomycin
13.7.2. Linezolid
13.7.3. Quinupristin/dalfopristin
13.7.4. Ampicillin
13.7.5. Chloramphenicol
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Drugs for Vancomycin-Resistant Enterococcus Faecium Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market: Market Share Analysis
14.2. Drugs for Vancomycin-Resistant Enterococcus Faecium Distributors and Customers
14.3. Drugs for Vancomycin-Resistant Enterococcus Faecium Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Alchemia Limited
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Alvogen
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Aphios Corporation
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Cellceutix Corporation
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Enanta Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Helix BioMedix
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. LegoChem Biosciences
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Lytix Biopharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. MGB Biopharma Limited
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Microbiotix
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook